Concentrations of Selected Adipokines, Interleukin-6, and Vitamin D in Patients with Papillary Thyroid Carcinoma in Respect to Thyroid Cancer Stages

Table 3

The comparison of anthropometric and biochemical parameters and clinical stage in the PTC patients depending on the presence/absence of the metabolic syndrome.

	Patients without the metabolic syndrome; 95 women, 14 men; (mean ± SD; median)	Patients with the metabolic syndrome; 56 women, 12 men; (mean ± SD; median)
Age	47.21 ± 14.45; 46	57.06 ± 11.54; 59.5	<0.001
BMI (kg/m^2)	26.19 ± 5.06; 26.15	31.11 ± 4.52; 31.06	<0.001
Waist (cm)	86.77 ± 13.75; 87	101.70 ± 11.96; 101	<0.001
WHR	0.83 ± 0.09; 0.82	0.91 ± 0.08; 0.90	<0.001
Glucose (mg/dL)	117.80 ± 22.30; 114	125.18 ± 29.22; 119	NS
TGs (mg/dL)	133.22 ± 67.16; 112	187.07 ± 61.44; 178	<0.001
HDL (mg/dL)	62.28 ± 18.32; 58	49.28 ± 16.65; 44.5	<0.001
Cholesterol (mg/dL)	281.22 ± 122.56; 231	271.04 ± 119.41; 230	NS
HOMA-IR	1.14 ± 0.65; 0.97	1.68 ± 1.25; 1.41	<0.001
Adiponectin (μg/mL)	15.66 ± 6.44; 15.0	13.64 ± 6.05; 13.0	<0.001
Leptin (ng/mL)	14.14 ± 10.26; 10.98	26.08 ± 24.52; 21.5	<0.001
Chemerin (ng/mL)	213.22 ± 49.22; 209	243.75 ± 44.79; 236	<0.001
Vitamin D (nmol/L)	67.53 ± 24.05; 61	63.02 ± 21.25; 60	NS
IL-6 (pg/mL)	2.49 ± 0.76; 2.29	3.01 ± 1.28; 2.83	<0.001
N (%) of patients with microcarcinomas	62 (56.88)	32 (47.06)	NS
N (%) of patients with
Stage I	94 (86.24)	50 (73.53)	<0.05
Stage II	14 (12.84)	17 (25)	<0.05
Stage III	1 (0.92)	0
Stage IV	0	1 (1.47)

NS = not significant.